Dianthus Therapeutics Inc... (DNTH)
Dianthus Therapeutics Inc. (DNTH) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 82.42 |
| Capitalización de mercado | 6.46B |
| Ingresos (TTM) | 1.9M |
| Beneficio neto (TTM) | -192.25M |
| Beta | 0.08 |
| EPS (TTM) | -4.27 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -24.36 |
| P/B (TTM) | 5.40 |
| P/S (TTM) | 3317.30 |
| Earnings Date | Nov 5, 2026 |
| Precio de venta | 146.7 |
| Volumen | 564,807 |
| Volumen medio (20D) | 1,069,050 |
| Abierto | 115.32 |
| Anterior Cerrar | 115.96 |
| Rango del día | 113.29 - 116.44 |
| Rango de 52 semanas | 20.69 - 116.47 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce...
Desempeño financiero
En 2025, los ingresos de Dianthus Therapeutics fueron 2.04M, una disminución de -67.35% en comparación con 6.24M del año anterior. Las ganancias fueron -162.34M, un aumento de 91.05%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
2 meses hace · Simply Wall St.
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks LingerDianthus Therapeutics reported a 75% response rate in a late-stage trial of claseprubart in CIDP. The update comes shortly after Sanofi discontinued a similar CIDP trial, leaving fewer competitors in ...
